Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy

BACKGROUND: Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of the tumor necrosis factor receptor superfamily t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guelen, Lars, Fischmann, Thierry O, Wong, Jerelyn, Mauze, Smita, Guadagnoli, Marco, Bąbała, Nikolina, Wagenaars, Jozef, Juan, Veronica, Rosen, David, Prosise, Winnie, Habraken, Maurice, Lodewijks, Imke, Gu, Danling, Stammen-Vogelzangs, Judith, Yu, Ying, Baker, Jeanne, Lutje Hulsik, David, Driessen-Engels, Lilian, Malashock, Dan, Kreijtz, Joost, Bertens, Astrid, de Vries, Evert, Bovens, Astrid, Bramer, Arne, Zhang, Yiwei, Wnek, Richard, Troth, Sean, Chartash, Elliot, Dobrenkov, Konstantin, Sadekova, Svetlana, van Elsas, Andrea, Cheung, Jason K, Fayadat-Dilman, Laurence, Borst, Jannie, Beebe, Amy M, Van Eenennaam, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472132/
https://www.ncbi.nlm.nih.gov/pubmed/36100308
http://dx.doi.org/10.1136/jitc-2022-005049

Ejemplares similares

Ejemplares similares